Systemic Angiotensinogen Concentrations Are Independently Associated With Left Ventricular Diastolic Function in a Community Sample

No abstract is available for this paper.

• Publication year

  2018

• Venue

  American Journal of Hypertension

• Publication date

  2018-01-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/ajh/hpx156PMID 28985347
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The renin-angiotensin-aldosterone system in heart failure for the non-specialist: the past, the present and the future

  2016cited by this paper
• Renin-angiotensin-aldosterone system blockers for heart failure with reduced ejection fraction or left ventricular dysfunction: Network meta-analysis.

  2016cited by this paper
• Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging.

  2016cited by this paper
• Plasma Aldosterone and Left Ventricular Diastolic Function in Treatment-Naïve Patients With Hypertension: Tissue-Doppler Imaging Study

  2015cited by this paper
• Association between urine aldosterone and diastolic function in patients with primary aldosteronism and essential hypertension.

  2014cited by this paper
• The M235T polymorphism in the angiotensinogen gene and heart failure: a meta-analysis

  2014cited by this paper
• Spironolactone for heart failure with preserved ejection fraction.

  2014cited by this paper
• Connective tissue growth factor and cardiac diastolic dysfunction: human data from the Taiwan Diastolic Heart Failure Registry and molecular basis by cellular and animal models

  2014cited by this paper
• Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy

  2014cited by this paper
• Differential relationships of systolic and diastolic blood pressure with components of left ventricular diastolic dysfunction

  2014cited by this paper
• Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial.

  2013cited by this paper
• Effects of Direct Renin Inhibition on Myocardial Fibrosis and Cardiac Fibroblast Function

  2013cited by this paper
• Inadequate RAAS suppression is associated with excessive left ventricular mass and systo-diastolic dysfunction

  2013cited by this paper
• Randomized Trial of Perindopril, Enalapril, Losartan and Telmisartan in Overweight or Obese Patients with Hypertension

  2013cited by this paper
• Contribution of Circulating Angiotensinogen Concentrations to Variations in Aldosterone and Blood Pressure in a Group of African Ancestry Depends on Salt Intake

  2012cited by this paper
• Contemporary Reviews in Cardiovascular Medicine The Progression of Hypertensive Heart Disease

  2011cited by this paper
• Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction.

  2011cited by this paper
• Role of the renin-angiotensin-aldosterone system and inflammatory processes in the development and progression of diastolic dysfunction.

  2009cited by this paper
• Nurse-recorded auscultatory blood pressure at a single visit predicts target organ changes as well as ambulatory blood pressure

  2009cited by this paper
• Irbesartan in patients with heart failure and preserved ejection fraction.

  2008cited by this paper
• Pathways involved in the transition from hypertension to hypertrophy to heart failure. Treatment strategies

  2008cited by this paper
• Heart failure with preserved ejection fraction: Clinical characteristics of 4133 patients enrolled in the I‐PRESERVE trial

  2008cited by this paper
• Molecular basis of diastolic dysfunction.

  2008cited by this paper
• Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system.

  2007cited by this paper
• FASTTRACK : The perindopril in elderly people with chronic heart failure (PEP-CHF) study

  2006cited by this paper
• Optimal Threshold Value for Left Ventricular Hypertrophy in Blacks: The Atherosclerosis Risk in Communities Study

  2005cited by this paper
• What Mechanisms Underlie Diastolic Dysfunction in Heart Failure?

  2004cited by this paper
• Angiotensinogen Gene Polymorphism, Plasma Angiotensinogen, and Risk of Hypertension and Ischemic Heart Disease: A Meta-Analysis

  2003cited by this paper
• Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic.

  2003cited by this paper
• Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial.

  2003cited by this paper
• Prognostic significance of left ventricular diastolic dysfunction in essential hypertension.

  2002cited by this paper
• Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study.

  2002cited by this paper
• Influence of plasma aldosterone on left ventricular geometry and diastolic function in treated essential hypertension.

  2002cited by this paper
• Predictive value of systolic and diastolic function for incident congestive heart failure in the elderly: the cardiovascular health study.

  2001cited by this paper
• Chronic antisense therapy for angiotensinogen on cardiac hypertrophy in spontaneously hypertensive rats.

  1999cited by this paper
• Relation between the renin-angiotensin-aldosterone system and left ventricular structure and function in young normotensive and mildly hypertensive subjects.

  1999cited by this paper
• Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators.

  1999cited by this paper
• Perindopril for elderly people with chronic heart failure: the PEP‐CHF study

  1999cited by this paper
• Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension.

  1998cited by this paper
• Opposite associations of circulating aldosterone and atrial natriuretic peptide with left ventricular diastolic function in essential hypertension

  1998cited by this paper
• Renin‐angiotensin system and myocardial collagen matrix: modulation of cardiac fibroblast function by angiotensin II type 1 receptor antagonism

  1997cited by this paper
• Molecular genetics of the renin-angiotensin-aldosterone system in human hypertension.

  1997cited by this paper
• Fibrous tissue and angiotensin II.

  1997cited by this paper
• Intracellular Ca2+ modulation by angiotensin II and endothelin-1 in cardiomyocytes and fibroblasts from hypertrophied hearts of spontaneously hypertensive rats.

  1996cited by this paper
• Controlling the false discovery rate: a practical and powerful approach to multiple testing

  1995cited by this paper
• The heart in hypertension.

  1992cited by this paper
• Pathological Hypertrophy and Cardiac Interstitium: Fibrosis and Renin‐Angiotensin‐Aldosterone System

  1991cited by this paper
• Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings.

  1986cited by this paper
• Recommendations Regarding Quantitation in M-Mode Echocardiography: Results of a Survey of Echocardiographic Measurements

  1978cited by this paper
• Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence of absence of asynergy.

  1976cited by this paper
• Kinetics of the human renin and human substrate reaction.

  1971cited by this paper

• The Cardiohepatic Axis in Metabolic Disease

  2025cites this paper
• Loss of Hepatic Angiotensinogen Attenuates Diastolic Dysfunction in Heart Failure with Preserved Ejection Fraction

  2025cites this paper
• Angiotensinogen: More Than Its Downstream Products: Evidence From Population Studies and Novel Therapeutics.

  2022cites this paper
• The emerging role of angiotensinogen in cardiovascular diseases

  2020cites this paper
• Sarcopenic Obesity in Heart Failure With Preserved Ejection Fraction

  2020cites this paper